Visceral fat: a key mediator of steatohepatitis in metabolic liver disease D van der Poorten, KL Milner, J Hui, A Hodge, MI Trenell, JG Kench, ... Hepatology 48 (2), 449-457, 2008 | 699 | 2008 |
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study N Bhala, P Angulo, D van der Poorten, E Lee, JM Hui, G Saracco, ... Hepatology 54 (4), 1208-1216, 2011 | 551 | 2011 |
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease KL Milner, D van der Poorten, A Xu, E Bugianesi, JG Kench, KSL Lam, ... Hepatology 49 (6), 1926-1934, 2009 | 231 | 2009 |
Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease LA Adams, J George, E Bugianesi, E Rossi, WB De Boer, ... Journal of gastroenterology and hepatology 26 (10), 1536-1543, 2011 | 216 | 2011 |
Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance KL Milner, D van der Poorten, M Trenell, AB Jenkins, A Xu, G Smythe, ... Gastroenterology 138 (3), 932-941. e3, 2010 | 172 | 2010 |
Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? D van der Poorten, CF Samer, M Ramezani‐Moghadam, S Coulter, ... Hepatology 57 (6), 2180-2188, 2013 | 169 | 2013 |
Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 160 | 2022 |
Twenty‐year audit of percutaneous liver biopsy in a major Australian teaching hospital D Van der Poorten, A Kwok, T Lam, L Ridley, DB Jones, MC Ngu, AU Lee Internal medicine journal 36 (11), 692-699, 2006 | 129 | 2006 |
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C K Thabet, A Asimakopoulos, M Shojaei, M Romero-Gomez, A Mangia, ... Nature communications 7 (1), 12757, 2016 | 121 | 2016 |
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes M Eslam, A Mangia, T Berg, HLY Chan, WL Irving, GJ Dore, ML Abate, ... Hepatology 64 (1), 34-46, 2016 | 115 | 2016 |
The gut microbiome M Sidhu, D van der Poorten Australian family physician 46 (4), 206-211, 2017 | 100 | 2017 |
The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice D Van der Poorten, PH Katelaris Alimentary pharmacology & therapeutics 26 (11‐12), 1537-1542, 2007 | 94 | 2007 |
Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease R Vongsuvanh, J George, D McLeod, D van der Poorten Journal of hepatology 57 (2), 392-398, 2012 | 83 | 2012 |
Visceral adiposity in gastrointestinal and hepatic carcinogenesis R Vongsuvanh, J George, L Qiao, D van der Poorten Cancer letters 330 (1), 1-10, 2013 | 78 | 2013 |
Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice C Haifer, CR Kelly, S Paramsothy, D Andresen, LE Papanicolas, ... Gut 69 (5), 801-810, 2020 | 70 | 2020 |
Midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma R Vongsuvanh, D van der Poorten, T Iseli, SI Strasser, GW McCaughan, ... PloS one 11 (5), e0155800, 2016 | 69 | 2016 |
Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion M Ramezani-Moghadam, J Wang, V Ho, TJ Iseli, B Alzahrani, A Xu, ... Journal of Biological Chemistry 290 (9), 5533-5542, 2015 | 67 | 2015 |
Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease V Gupta, XJ Mah, MC Garcia, C Antonypillai, D van der Poorten World Journal of Gastroenterology: WJG 21 (37), 10621, 2015 | 64 | 2015 |
Hepatitis C virus induces the cannabinoid receptor 1 D van der Poorten, M Shahidi, E Tay, J Sesha, K Tran, D McLeod, ... PLoS One 5 (9), e12841, 2010 | 62 | 2010 |
Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease FCF Chang, V Kwan, D van der Poorten, N Mahant, N Wolfe, AD Ha, ... Journal of Clinical Neuroscience 25, 41-45, 2016 | 49 | 2016 |